The β-strand D of transthyretin trapped in two discrete conformations

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1700, Issue 1, 2004, Pages 93-104

  Hörnberg, Andreas ^a   Olofsson, Anders ^a   Eneqvist, Therese ^a,b   Lundgren, Erik ^a   Sauer Eriksson, A Elisabeth ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b STOCKHOLM UNIVERSITY   (Sweden)

Author keywords

Amyloid; amyloid TTR; ATTR; familial amyloidotic polyneuropathy; Familial amyloidotic polyneuropathy; FAP; senile systemic amyloidosis; SSA; Transthyretin; transthyretin; TTR; TTR A108Y L110EP21212; Variant Ala108Tyr Leu110Glu; X ray structure

Indexed keywords

ALANINE; GLUTAMIC ACID; LEUCINE; PREALBUMIN; TYROSINE;

ARTICLE; CRYSTAL STRUCTURE; CRYSTALLIZATION; HYDROGEN BOND; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN ENGINEERING; PROTEIN STABILITY; PROTEIN STRUCTURE; PROTEIN VARIANT; THERMODYNAMICS; WILD TYPE;

CRYSTALLOGRAPHY, X-RAY; DIMERIZATION; HUMANS; HYDROGEN BONDING; HYDROGEN-ION CONCENTRATION; MODELS, MOLECULAR; MUTATION; PREALBUMIN; PROTEIN CONFORMATION; PROTEIN DENATURATION;

EID: 2942701887     PISSN: 15709639     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbapap.2004.04.004     Document Type: Article

References (58)

1. Kelly J.W. Alternative conformations of amyloidogenic proteins govern their behavior. Curr. Opin. Struct. Biol. 6:1996;11-17
2. Pepys M.D. Samter M. Immunological Diseases. 1998;631-674 Little, Brown & Company, Boston
3. Rochet J.C., Lansbury P.T. Jr. Amyloid fibrillogenesis: themes and variations. Curr. Opin. Struct. Biol. 10:2000;60-68
4. Ghiso J., Frangione B. Amyloidosis and Alzheimer's disease. Adv. Drug Deliv. Rev. 54:2002;1539-1551
5. Saraiva M.J. Transthyretin mutations in health and disease. Hum. Mutat. 5:1995;191-196
6. Benson M.D., Uemichi T. Transthyretin amyloidosis. Amyloid: Int. J. Exp. Clin. Invest. 3:1996;44-56
7. Hamilton J.A., Benson M.D. Transthyretin: a review from a structural perspective. Cell. Mol. Life Sci. 58:2001;1491-1521
8. Connors L.H., Richardson A.M., Théberge R., Costello C.E. Tabulation of transthyretin (TTR) variants as of 1/1/2000. Amyloid: Int. J. Exp. Clin. Invest. 7:2000;54-69
9. Eneqvist T., Sauer-Eriksson A.E. Structural distribution of mutations associated with familial amyloidotic polyneuropathy in human transthyretin. Amyloid: Int. J. Exp. Clin. Invest. 8(3):2001;149-168
10. Westermark P., Sletten K., Johansson B., Cornwell G.G.D. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc. Natl. Acad. Sci. U. S. A. 87:1990;2843-2845
11. Blake C.C., Geisow M.J., Oatley S.J., Rérat B., Rérat C. Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 Å J. Mol. Biol. 121:1978;339-356
12. Hamilton J.A., Steinrauf L.K., Braden B.C., Liepnieks J., Benson M.D., Holmgren G., Sandgren O., Steen L. The X-ray crystal structure refinements of normal human transthyretin and the amyloidogenic Val-30→Met variant to 1.7-Å resolution. J. Biol. Chem. 268:1993;2416-2424
13. Hörnberg A., Eneqvist T., Olofsson A., Lundgren E., Sauer-Eriksson A.E. A comparative analysis of 23 structures of the amyloidogenic protein transthyretin. J. Mol. Biol. 302:2000;649-669
14. Sebastião M.P., Saraiva M.J., Damas A.M. The crystal structure of amyloidogenic Leu55→Pro transthyretin variant reveals a possible pathway for transthyretin polymerization into amyloid fibrils. J. Biol. Chem. 273:1998;24715-24722
15. Schormann N., Murrell J.R., Benson M.D. Tertiary structures of amyloidogenic and non-amyloidogenic transthyretin variants: new model for amyloid fibril formation. Amyloid: Int. J. Exp. Clin. Invest. 5:1998;175-187
16. Sebastiao M.P., Lamzin V., Saraiva M.J., Damas A.M. Transthyretin stability as a key factor in amyloidogenesis: X-ray analysis at atomic resolution. J. Mol. Biol. 306:2001;733-744
17. Eneqvist T., Olofsson A., Ando Y., Miyakawa T., Katsuragi S., Jass J., Lundgren E., Sauer-Eriksson A.E. Disulfide-bond formation in the transthyretin mutant Y114C prevents amyloid fibril formation in vivo and in vitro. Biochemistry. 41:2002;13143-13151
18. Goldsteins G., Andersson K., Olofsson A., Dacklin I., Edvinsson Å., Baranov V., Sandgren O., Thylén C., Hammarstrom S., Lundgren E. Characterization of two highly amyloidogenic mutants of transthyretin. Biochemistry. 36:1997;5346-5352
19. Eneqvist T., Andersson K., Olofsson A., Lundgren E., Sauer-Eriksson A.E. The β-slip: a novel concept in transthyretin amyloidosis. Mol. Cell. 6:2000;1207-1218
20. Hammarström P., Jiang X., Deechongkit S., Kelly J.W. Anion shielding of electrostatic repulsions in transthyretin modulates stability and amyloidosis: insight into the chaotrope unfolding dichotomy. Biochemistry. 40:2001;11453-11459
21. Lai Z., Colón W., Kelly J.W. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. Biochemistry. 35:1996;6470-6482
22. McPherson A. Preparation and Analysis of Protein Crystals. 1982;Wiley, New York
23. Sauer U.H., Ceska T.A. A simple method for making reproducible fibre loops for protein cryocrystallography. J. Appl. Crystallogr. 30:1997;71-72
24. Otwinowski Z., Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276:1997;307-326
25. N. Collaborative Computational Project The CCP4 suite: programs for protein crystallography. Acta Crystallogr., D. 50:1994;760-763
26. Brünger A.T., Adams P.D., Clore G.M., DeLano W.L., Gros P., Grosse-Kunstleve R.W., Jiang J.S., Kuszewski J., Nilges M., Pannu N.S., Read R.J., Rice L.M., Simonson T., Warren G.L. Crystallography and NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr., D. 54:1998;905-921
27. Brünger A.T. Free R value: a novel statistical quantity for assessing the accuracy of crystal structures. Nature. 355:1992;472-474
28. Murshudov G.N., Vagin A.A., Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr., D. 53:1997;240-255
29. Jones T.A., Zou J.Y., Cowan S.W., Kjeldgaard M. Improved methods for binding protein models in electron density maps and the location of errors in these models. Acta Crystallogr., A. 47:1991;110-119
30. Laskowski R.A., Moss D.S., Thornton J.M. Main-chain bond lengths and bond angles in protein structures. J. Mol. Biol. 231:1993;1049-1067
31. Lee B., Richards F.M. The interpretation of protein structures: estimation of static accessibility. J. Mol. Biol. 55:1971;379-400
32. Kleywegt G.J. Use of non-crystallographic symmetry in protein structure refinement. Acta Crystallogr., D. 52:1996;842-857
33. Harris M., Jones T.A. Molray - a web interface between O and the POV-Ray ray tracer. Acta Crystallogr., D Biol. Crystallogr. 57:2001;1201-1203
34. Kraulis P.J. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallogr. 24:1991;946-950
35. Merritt E.A., Bacon D.J. Raster3D: photorealistic molecular graphics. Methods Enzymol. 277:1997;505-524
36. Hammarström P., Jiang X., Hurshman A.R., Powers E.T., Kelly J.W. Sequence-dependent denaturation energetics: a major determinant in amyloid disease diversity. Proc. Natl. Acad. Sci. U. S. A. 99(Suppl. 4):2002;16427-16432
37. McCutchen S.L., Kelly J.W. Intermolecular disulfide linkages are not required for transthyretin amyloid fibril formation in vitro. Biochem. Biophys. Res. Commun. 197:1993;415-421
38. McCutchen S.L., Lai Z., Miroy G.J., Kelly J.W., Colon W. Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease. Biochemistry. 34:1995;13527-13536
39. Quintas A., Saraiva M.J., Brito R.M. The amyloidogenic potential of transthyretin variants correlates with their tendency to aggregate in solution. FEBS Lett. 418:1997;297-300
40. Lashuel H.A., Lai Z., Kelly J.W. Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: implications for wild-type, V30M, and L55P amyloid fibril formation. Biochemistry. 37:1998;17851-17864
41. Nettleton E.J., Sunde M., Lai Z., Kelly J.W., Dobson C.M., Robinson C.V. Protein subunit interactions and structural integrity of amyloidogenic transthyretins: evidence from electrospray mass spectrometry. J. Mol. Biol. 281:1998;553-564
42. Kelly J.W. The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Curr. Opin. Struct. Biol. 8:1998;101-106
43. McCammon M.G., Scott D.J., Keetch C.A., Greene L.H., Purkey H.E., Petrassi H.M., Kelly J.W., Robinson C.V. Screening transthyretin amyloid fibril inhibitors: characterization of novel multiprotein, multiligand complexes by mass spectrometry. Structure (Camb). 10:2002;851-863
44. Serpell L.C., Goldsteins G., Dacklin I., Lundgren E., Blake C.C.F. The "edge strand" hypothesis: prediction and test of a mutational "hot-spot" on the transthyretin molecule associated with FAP amyloidogenesis. Amyloid: Int. J. Exp. Clin. Invest. 3:1996;75-85
45. Yang M., Lei M., Huo S. Why is Leu55→Pro55 transthyretin variant the most amyloidogenic: Insights from molecular dynamics simulations of transthyretin monomers. Protein Sci. 12:2003;1222-1231
46. Liu K., Cho H.S., Hoyt D.W., Nguyen T.N., Olds P., Kelly J.W., Wemmer D.E. Deuterium-proton exchange on the native wild-type transthyretin tetramer identifies the stable core of the individual subunits and indicates mobility at the subunit interface. J. Mol. Biol. 303:2000;555-565
47. Liu K., Kelly J.W., Wemmer D.E. Native state hydrogen exchange study of suppressor and pathogenic variants of transthyretin. J. Mol. Biol. 320:2002;821-832
48. Olofsson A., Ippel J.H., Wijmenga S.S., Lundgren E., Ohman A. Probing solvent accessibility of transthyretin-amyloid by solution NMR spectroscopy. J. Biol. Chem. 279:2004;5699-5707
49. Serag A.A., Altenbach C., Gingery M., Hubbell W.L., Yeates T.O. Identification of a subunit interface in transthyretin amyloid fibrils: evidence for self-assembly from oligomeric building blocks. Biochemistry. 40:2001;9089-9096
50. Serag A.A., Altenbach C., Gingery M., Hubbell W.L., Yeates T.O. Arrangement of subunits and ordering of beta-strands in an amyloid sheet. Nat. Struct. Biol. 9:2002;734-739
51. Kelly J.W., Lansbury P.T. A chemical approach to elucidate the mechanism of transthyretin and β-protein amyloid fibril formation. Amyloid: Int. J. Exp. Clin. Invest. 1:1994;186-205
52. Peterson S.A., Klabunde T., Lashuel H.A., Purkey H., Sacchettini J.C., Kelly J.W. Inhibiting transthyretin conformational changes that lead to amyloid fibril formation. Proc. Natl. Acad. Sci. U. S. A. 95:1998;12956-12960
53. Klabunde T., Petrassi H.M., Oza V.B., Raman P., Kelly J.W., Sacchettini J.C. Rational design of potent human transthyretin amyloid disease inhibitors. (published erratum appears in Nat. Struct. Biol. (2000) May; 7 (5) 431) Nat. Struct. Biol. 7:2000;312-321
54. Ghosh M., Meerts I.A., Cook A., Bergman A., Brouwer A., Johnson L.N. Structure of human transthyretin complexed with bromophenols: a new mode of binding. (in process citation) Acta Crystallogr., D. 56:2000;1085-1095
55. Wojtczak A., Neumann P., Cody V. Structure of a new polymorphic monoclinic form of human transthyretin at 3 Å resolution reveals a mixed complex between unliganded and T4-bound tetramers of TTR. Acta Crystallogr., D. 57:2001;957-967
56. Jacobson D.R., McFarlin D.E., Kane I., Buxbaum J.N. Transthyretin Pro55, a variant associated with early-onset, aggressive, diffuse amyloidosis with cardiac and neurologic involvement. Hum. Genet. 89:1992;353-356
57. McCutchen S.L., Colon W., Kelly J.W. Transthyretin mutation Leu-55-Pro significantly alters tetramer stability and increases amyloidogenicity. Biochemistry. 32:1993;12119-12127
58. Lashuel H.A., Wurth C., Woo L., Kelly J.W. The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions. Biochemistry. 38:1999;13560-13573